Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in caucasians

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 7-14

  Legrand Andreoletti M ^a   Stucker I ^b   Marez, D ^a   Galais, P ^b   Cosme, J ^b   Sabbagh, N ^a   Spire, C ^a   Cenee S ^b   Lafitte, J J ^a   Beaune, P ^b   Broly, F ^a  

^a UNIV LILLE   (France)

^b INSERM   (France)

Author keywords

CYP2D6; Lung cancer; P450 2D6; PCR SSCP

Indexed keywords

CYTOCHROME P450;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; SMALL CELL CARCINOMA; SMOKING;

ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FRANCE; GENE FREQUENCY; GENE REARRANGEMENT; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MULTIGENE FAMILY; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 15444339987     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00002     Document Type: Article

References (47)

1. Agúndez JAG, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, Rodriguez A, Jara C, Benitez J. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55, 10-14.
2. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57, 265-269.
3. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312, 169-170.
4. Bell DA. Detection of DNA sequence polymorphisms in carcinogen metabolism genes by polymerase chain reaction. Environ Mol Mutagen 1991; 18, 245-248.
5. Benitez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E, Munoz JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 1991; 27, 158-161.
6. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996; 56, 251-253.
7. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: analysis of Common Mutations and Alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10, 545-558.
8. Broly F, Marez D, Lo-Guidice JM, Sabbagh N, Legrand M, Boone P, Meyer UA. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 1995a; 96, 601-603.
9. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo-Guidice JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Phamacogenetics 1995b; 5, 373-384.
10. Caporaso N, Haves RB, Dosemeci M, Hoover R, Ayesh R, Hetzel M, Idle J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res 1989a; 49, 3675-3679.
11. Caporaso N, Pickle LW, Bale S, Ayesh R, Hetzel M, Idle J. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Genet Epidemiol 1989b; 6, 517-524.
12. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muschik GM, Green-Gallo L, Buivys D, Aisner S et al. Lung cancer and the Debrisoquine Metabolic Phenotype. J Natl Cancer I 1990; 82, 1264-1272.
13. Caporaso N, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, Sugimura H, Weston A, Harris CC. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassificalion for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Persp 1992; 98, 101-105.
14. Caporaso N, DeBaun MR, Rothman N. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetica 1995; 5, S129-S134.
15. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochroine P4502D6. Carcinogenesis 1991; 12, 1197-1201.
16. D'Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996; 1, 149-175.
17. Dabi ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274, 516-520.
18. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Therapeut 1995; 57, 129-160.
19. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WH, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6, 193-201.
20. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995; 16, 2675-2678.
21. Duche JC, Joanne C, Barre J, De Cremoux H, Dalphin JC, Depierre A, Brochard P, Tillement JP, Bechtel P. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 1991; 31, 533-536.
22. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23, 455-458.
23. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA. Human Debrisoquine 4-Hydroxylase (P450IID1): cDNA and Deduced Amino Acid Sequence and Assignment of the CYP2D Locus to Chromosome 22. Genomics 1988; 2, 174-179.
24. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H. Metabolic cytochroine P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 1992; 2, 259-263.
25. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYT2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993a; 3, 19-27.
26. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ Health Persp 1993b; 101 (suppl.3), 109-112.
27. Johansson I, Lundqvist F, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90, 11825-11829.
28. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The Human Debrisoquine 4-Hvdroxylase (CYP2D) Locus: sequence and Identification of the Polymorphic CYP2D6 Gene, a Related Gene, and a Pseudogene. Am J Hum Genet 1989; 45, 889-904.
29. Law MR, Hetzel MR, Idle JR. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989; 59, 686-687.
30. Legrand M, Stücker I, Marez D, Sabbagh N, Lo-Guidice JM, Broly F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis 1996; 17, 2267-2269.
31. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiat Scand 1993; 87, 23-28.
32. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. Pharmacogenetics 1994; 4, 107-108.
33. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Bonne P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995; 5, 305-311.
34. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996; 97, 668-670.
35. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7, 193-202.
36. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 1988; 66, 87-97.
37. Roots I, Brockmöller J, Drakoulis N, Loddenkemper R. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Investigator 1992; 70, 307-319.
38. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60, 284-295.
39. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. Are poor metabolizers of sparteine/debrisoquine less pain tolerant than extensive melabolizers. Pain 1993; 53, 335-339.
40. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85, 5240-5243.
41. Smith CAD, Moss JE, Cough AC, Spurr NK, Wolf CR. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Persp 1992; 98, 107-112.
42. Smith G, Stanley LA, Sim H, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25, 27-65.
43. Speirs CJ, Murray S, Davies DS, Biola Mabadeje AF, Boobis AR. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 1990; 29, 101-109.
44. Stücker I, Cosine J, Laurent Ph, Cenée S, Beaune Ph, Bignon J, Depierre A, Milleron B, Hémon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 1995; 16, 2759-2764.
45. Sugimura H, Caporaso NF, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Western A, Harris CC. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis 1990; 11, 1527-1530.
46. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A, Borresen AL. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994; 4, 47-57.
47. Wolf CR, Smith CAD, Cough AC, Moss JL, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13, 1035-1038.